Tekla Capital Management LLC bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,750 shares of the medical equipment provider’s stock, valued at approximately $1,687,000.
Other large investors have also recently modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in shares of ABIOMED by 65.0% in the second quarter. Wells Fargo & Company MN now owns 134,542 shares of the medical equipment provider’s stock valued at $55,034,000 after acquiring an additional 52,986 shares in the last quarter. Beech Hill Advisors Inc. lifted its stake in shares of ABIOMED by 100.0% in the third quarter. Beech Hill Advisors Inc. now owns 1,000 shares of the medical equipment provider’s stock valued at $450,000 after purchasing an additional 500 shares during the period. Private Advisor Group LLC acquired a new stake in shares of ABIOMED in the second quarter valued at about $1,515,000. State of Alaska Department of Revenue lifted its stake in shares of ABIOMED by 4.4% in the third quarter. State of Alaska Department of Revenue now owns 7,184 shares of the medical equipment provider’s stock valued at $3,230,000 after purchasing an additional 304 shares during the period. Finally, Creative Planning lifted its stake in shares of ABIOMED by 5.3% in the third quarter. Creative Planning now owns 10,593 shares of the medical equipment provider’s stock valued at $4,764,000 after purchasing an additional 533 shares during the period. 87.27% of the stock is currently owned by institutional investors and hedge funds.
Shares of ABMD opened at $327.18 on Wednesday. The stock has a market cap of $14.98 billion, a price-to-earnings ratio of 133.54, a price-to-earnings-growth ratio of 2.80 and a beta of 0.28. ABIOMED, Inc. has a 12-month low of $186.72 and a 12-month high of $459.75.
ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.36. The company had revenue of $181.78 million during the quarter, compared to analysts’ expectations of $175.41 million. ABIOMED had a net margin of 27.60% and a return on equity of 20.09%. The firm’s quarterly revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.54 earnings per share. Equities analysts expect that ABIOMED, Inc. will post 3.57 EPS for the current year.
Several brokerages recently commented on ABMD. BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective for the company in a research note on Friday, November 2nd. Morgan Stanley raised their price objective on shares of ABIOMED from $370.00 to $396.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Finally, ValuEngine upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Wednesday, November 28th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $402.78.
In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the completion of the transaction, the vice president now owns 48,954 shares in the company, valued at $21,172,605. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Tekla Capital Management LLC Buys New Holdings in ABIOMED, Inc. (ABMD)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/05/tekla-capital-management-llc-buys-new-holdings-in-abiomed-inc-abmd.html.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Read More: What is a stock buyback?
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.